EUVIMEDEUVIMED entdecken
Crossref

Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients

Ava M Sanayei, Adriana Montalvan, Isabella Faria, Julia Ochalla, Martha Pavlakis, Barbra M Blair, Carolyn D Alonso, Michael Curry, Behnam Saberi

Transplantation Proceedings · 2023

DOI: 10.1016/j.transproceed.2023.07.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2023. Verfasst von Ava M Sanayei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: COVID-19, Organ Transplantation, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: SARS-CoV-2 infection in solid organ transplant (SOT) recipients is associated with high morbidity and mortality. Tixagevimab/cilgavimab monoclonal antibodies were previously authorized for pre-exposure prophylaxis for immunocompromised individuals. We aimed to determine if tixagevimab/cilgavimab could prevent breakthrough SARS-CoV-2 infection in SOT recipients. MATERIAL AND METHODS: We conducted a prospective single-center study of SOT recipients who received tixagevimab/cilgavimab compared with those who did not. Demographics, type of transplant, immunosuppression regimen, COVID-19 vaccination status, and tixagevimab/cilgavimab administration data were collected. Participants were interviewed for 6 months or until they tested positive for SARS-CoV-2, whichever came first. Kaplan-Meier SARS-CoV-2-free survival curves were created based on the tixagevimab/cilgavimab administration date and SARS-CoV-2 infection. The log-rank test was used for comparison. Univariate and multivariate Cox regression models were constructed. RESULTS: The study cohort included 323 patients. Two hundred forty-eight received tixagevimab/cilgavimab, and 75 did not (control). COVID-19 vaccination rate was higher among tixagevimab/cilgavimab recipients than nontixagevimab/cilgavimab recipients (99.6% vs 92.0%; P < .001). Twenty-six patients in the tixagevimab/cilgavimab group (10.5%) and 23 in the control group (30.7%) tested positive for SARS-CoV-2 infection (P < .001). In a multivariate analysis, receipt of tixagevimab/cilgavimab and duration from transplant were both associated with reduced risk of SARS-CoV-2 infection (hazard ratio 0.431; 95% CI 0.224-0.828 and hazard ratio 0.917; 95% CI 0.861-0.978, respectively). CONCLUSION: During the study period, SOT recipients who received tixagevimab/cilgavimab had a significantly lower rate of SARS-CoV-2 infection. There were no differences in symptom frequency, illness severity, hospitalization rate, or treatment of SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Organ TransplantationAntibodies, Monoclonal, HumanizedHumansMaleMiddle AgedFemaleProspective StudiesSARS-CoV-2AgedAdultTransplant RecipientsImmunosuppressive Agents

Substanzen

Antibodies, Monoclonal, HumanizedImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Division of Transplant Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: bsaberi@bidmc.harvard.edu.

Zitieren

APA

Sanayei, A. M., Montalvan, A., Faria, I., Ochalla, J., Pavlakis, M., Blair, B. M., Alonso, C. D., Curry, M., & Saberi, B. (2023). Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.07.011

Vancouver

Sanayei AM, Montalvan A, Faria I, Ochalla J, Pavlakis M, Blair BM, et al. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients. Transplantation Proceedings. 2023. doi:10.1016/j.transproceed.2023.07.011

BibTeX
@article{Sanayei2023,
  author = {Sanayei, Ava M and Montalvan, Adriana and Faria, Isabella and Ochalla, Julia and Pavlakis, Martha and Blair, Barbra M and Alonso, Carolyn D and Curry, Michael and Saberi, Behnam},
  title = {Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients},
  journal = {Transplantation Proceedings},
  year = {2023},
  doi = {10.1016/j.transproceed.2023.07.011}
}
Kostenlos starten →